Our work takes this in a different direction by demonstrating that CD155 can be directly targeted with CD155 CAR-T cells in preclinical models, demonstrating feasibility and effectiveness for both AML and solid tumor malignancies. The gene discussed is PVR; the disease is acute myeloid leukemia.